Human Respiratory Syncytial Virus Subgroup A and B Infections in Nasal, Bronchial, Small-Airway, and Organoid-Derived Respiratory Cultures

L. C. Rijsbergen,a M. M. Lamers,a A. D. Comvalius,a R. W. Koutstaal,a D. Schipper, W. P. Duprex,b B. L. Haagmans,a R. D. de Vries,a R. L. de Swarta

aDepartment of Viroscience, Postgraduate School of Molecular Medicine, Erasmus MC, Rotterdam, the Netherlands
bCenter for Vaccine Research, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

ABSTRACT  Human respiratory syncytial virus (HRSV) is the leading cause of bronchiolitis in infants. Two subgroups of HRSV (A and B) routinely cocirculate. Most research has been performed with HRSV-A strains because these are easier to culture than HRSV-B strains. In this study, we aimed to compare the replicative fitness and HRSV-induced innate cytokine responses of HRSV-A and HRSV-B strains in disease-relevant cell culture models. We used two recombinant (r) clinical isolate-based HRSV strains (A11 and B05) and one recombinant laboratory-adapted HRSV strain (A2) to infect commercially available nasal, bronchial, and small-airway cultures. Epithelial cells from all anatomical locations were susceptible to HRSV infection despite the induction of a dominant type III interferon response. Subgroup A viruses disseminated and replicated faster than the subgroup B virus. Additionally, we studied HRSV infection and innate responses in airway organoids (AOs) cultured at air-liquid interface (ALI). Results were similar to the commercially obtained bronchial cells. In summary, we show that HRSV replicates well in cells from both the upper and the lower airways, with a slight replicative advantage for subgroup A viruses. Lastly, we showed that AOs cultured at ALI are a valuable model for studying HRSV ex vivo and that they can be used in the future to study factors that influence HRSV disease severity.

IMPORTANCE  Human respiratory syncytial virus (HRSV) is the major cause of bronchiolitis and pneumonia in young infants and causes almost 200,000 deaths per year. Currently, there is no vaccine or treatment available, only a prophylactic monoclonal antibody (palivizumab). An important question in HRSV pathogenesis research is why only a fraction (1 to 3%) of infants develop severe disease. Model systems comprising disease-relevant HRSV isolates and accurate and reproducible cell culture models are indispensable to study infection, replication, and innate immune responses. Here, we used differentiated AOs cultured at ALI to model the human airways. Subgroup A viruses replicated better than subgroup B viruses, which we speculate fits with epidemiological findings that subgroup A viruses cause more severe disease in infants. By using AOs cultured at ALI, we present a highly relevant, robust, and reproducible model that allows for future studies into what drives severe HRSV disease.

KEYWORDS  air-liquid interface, airway organoids, cytokines, human airway epithelial cells, interferons, respiratory syncytial virus
a lower respiratory tract infection (LRTI) such as bronchiolitis or pneumonia, leading to hospitalization in 1 to 3% of the infants (3). The burden of HRSV is substantial in the elderly as well; at least 10% of winter hospitalizations are due to HRSV, with a case fatality rate of almost 10% (4). HRSV infection does not lead to protective immunity, and reinfections can occur throughout life (5, 6). Treatment options for HRSV are limited. Palivizumab is a humanized monoclonal antibody specific for the HRSV fusion (F) glycoprotein and is used as prophylaxis but is expensive and only given to infants at high risk (7, 8). Recently, another humanized monoclonal antibody against HRSV was developed (nirsevimab) (9). Ribavirin, a nucleoside analogue, is an approved drug for treating HRSV infection, but its effectiveness is disputed (10). Despite many efforts to develop an HRSV vaccine, none have been licensed (11).

HRSV is predominantly transmitted via direct contact or large droplets and targets epithelial cells in the respiratory tract (12). HRSV replication and the ensuing host inflammatory response can lead to damage of the epithelial layer. Exposure usually results in an upper respiratory tract infection (URTI), and symptoms include congestion, sneezing, and rhinorrhea (2, 13). In some cases, HRSV spreads to the lower respiratory tract and infects ciliated epithelial cells of the bronchi and terminal bronchioles (14, 15). Subsequent epithelial damage, combined with an influx of white blood cells and mucus production, can lead to mucus plugging and occlusion of the airway lumina. This results in airway obstruction and air trapping, causing apnea, difficulty breathing, and wheezing. This effect is most pronounced in infants, where the airways are still exceptionally small (13, 14). Complications in adults are associated with acute bronchitis, pneumonia, and exacerbations of chronic obstructive pulmonary disease or asthma. Where severe HRSV disease in infants is often associated with immune hyperresponsiveness, in adults, it is associated with hyporesponsiveness, which could be caused by compromised or waning immunity (1, 2).

We only have a rudimentary understanding of the development of severe HRSV disease. This is partly due to the fact that many studies have been performed in model systems that do not accurately reflect the in vivo situation. Immortalized cell lines like HEp-2, A549, BEAS-2B, and Vero cells are frequently used. However, these cells poorly reflect the natural target cells for HRSV and potentially do not express the relevant cellular entry receptors. Studies in these immortalized cell lines can lead to spurious observations on entry, dissemination, and infectivity (16, 17).

Well-differentiated (wd) primary human airway epithelial models are an attractive cell culture model to study respiratory virus-host interactions. These primary human airway cultures are differentiated at the air-liquid interface (ALI) to polarized epithelial cell cultures that mimic the human respiratory tract and include the natural target cell for HRSV, ciliated epithelial cells (12, 17–20). A more recently developed model system to study respiratory virus-host interactions is based on airway organoids (AOs) (21). AOs are stem cell based, meaning that they have self-renewing capacities and thus offer an unlimited supply of cells, increasing experimental reproducibility. HRSV infection of differentiated AOs grown in Matrigel led to similar phenomena as observed in infants in vivo, such as swelling, detachment, and sloughing of cells into the lumen (22–24). AOs cultured at ALI can be differentiated into a pseudostratified epithelium that includes polarized ciliated epithelial cells and can also be used as a model for HRSV studies (25).

Two HRSV subgroups, HRSV-A and HRSV-B, cocirculate globally. Although both can cause severe HRSV disease, HRSV-A strains are typically associated with more severe disease than HRSV-B strains (26). Additionally, most HRSV studies are performed with subgroup A strains because these are easier to propagate than HRSV-B strains (16). Our aim in this study was to compare the replicative fitness and HRSV-induced innate cytokine responses of HRSV-A and HRSV-B strains in disease-relevant cell culture models. We used a recombinant (r) HRSV-A and an HRSV-B strain, both based on clinical isolates [rHRSV\textsuperscript{A11}EGFP(5)] (27), and [rHRSV\textsuperscript{B05}EGFP(5) (28) or rHRSV\textsuperscript{B05}dTom(5)] (27), referred to [rHRSV\textsuperscript{A11}] and [rHRSV\textsuperscript{B05}], and a laboratory-adapted rHRSV-A [rHRSV\textsuperscript{A16}EGFP(5)], referred to as rHRSV\textsuperscript{A16} to infect nasal, bronchial, and small-airway cultures obtained from epithelium.
All viruses expressed enhanced green fluorescent protein (EGFP) or dTomato (dTom) as a reporter protein from the 5th position in the genome, facilitating sensitive detection of HRSV-infected cells in the absence of visible cytopathic changes. We found nasal, bronchial, or small-airway cultures (SACs) were all susceptible to HRSV infection, despite induction of a type III interferon (IFN) response. This was recapitulated in AOs grown at ALI that resembled the bronchial cultures. Subgroup A viruses replicated to higher titers of cell-free virus than the subgroup B virus in all our cultures at 3 days postinfection (DPI), but the clinical isolates resulted in more infected cells (measured as percentage of virus-positive area) at 2 DPI. HRSV infection led to visible cytopathic effects, such as rounding of ciliated cells, cilia disruption, shorter cilia, and formation of small syncytia. Viral loads correlated with the production of innate cytokines, dominated by type III IFN.

RESULTS

Replication kinetics in well-differentiated nasal, bronchial, and small-airway cultures. Well-differentiated airway cultures from the nose, bronchus, and SACs (bronchioles) were purchased from Epithelix and infected with a relatively low inoculum of rHRSVA2 (laboratory adapted), rHRSVA11, and rHRSVB05 (clinical isolate based). After a single round of replication (24 h), we detected slightly more foci of HRSV infection in nasal and bronchial cells than in the SACs (Fig. S1 in the supplemental material). This shows that with a standardized inoculum and single replication cycle, differences in susceptibility and permissiveness between the cells could already be shown. Further dissemination was studied by measuring the production of cell-free virus and the surface area of HRSV-infected cells based on fluorescence over time (Fig. 1). Both rHRSV-A strains replicated to significantly higher cell-free viral titers ($\pm 10^6$ to $10^7$ 50% tissue culture infective dose [TCID$_{50}$/ml]) than the rHRSV-B strain ($10^4$ TCID$_{50}$/ml) over time, especially in nasal and bronchial cultures. However, the percentage of EGFP-positive (EGFP$^+$) surface area at 1 and 2 DPI was significantly higher for both clinical isolate-based strains than for the laboratory-adapted strain. The clinical-based rHRSVA11 virus disseminated to a higher infected surface area than the clinical-based rHRSVB05.

Cytopathology in well-differentiated nasal, bronchial, and small-airway cultures. To assess the tropism of HRSV and the associated cytopathic effect (CPE) in primary cultures, we performed a histological analysis of airway cultures at 3 DPI, in combination with indirect immunofluorescence staining (IIF). The uninfected nasal and bronchial cultures consisted of a pseudostratified epithelium, and ciliated cells were abundantly present at the apical side (Fig. 2A and C [bronchial]; Fig. S2A and C [nasal]). In the HRSV-infected nasal and bronchial cultures, infected cells were mainly present at the apical side of the epithelium and were predominantly ciliated epithelial cells. We observed hyperplasia of HRSV-infected cells and the formation of small channels in the culture (Fig. 2A and B; Fig. S2A and B). Microscopically, we observed an increase in mucus production, and cilia actively transported the mucus through these channels (data not shown). These alterations were not observed in the uninfected cultures. Furthermore, we observed cilia degeneration (shortened and damaged cilia, rounding of ciliated cells) and damaged cell layer, the latter visualized by the loss of tight junctions caused by small syncytium formation, in both nasal and bronchial cultures (Fig. 2C and D; Fig. S2C and D). Differences in CPE between rHRSV-A and rHRSV-B strains were not observed. Compared to nasal and bronchial cultures, uninfected SACs contained a thinner basal cell layer and fewer ciliated epithelial cells (Fig. S3A and C). In SACs, HRSV also mainly targeted ciliated epithelial cells (Fig. S3B and D), but the infection was more focal than the nasal and bronchial cultures. We observed infected cell hyperplasia compared to the uninfected control throughout the epithelial layer, but cilia and tight junctions remained intact (Fig. S3A and B).

Cytokine responses in well-differentiated nasal, bronchial, and small-airway cultures. To evaluate the antiviral response of primary differentiated epithelial cells to HRSV infection, we harvested apical and basolateral washes at 1, 2, and 3 DPI and measured cytokine levels. Cytokines were predominantly detected in the apical washes. Type III interferons (IFN) (interleukin 28 A and B [IL-28A/B] and IL-29) were the main cytokines produced in all airway cultures. IL-29 increased at least 100-fold
compared to uninfected cultures. IL-28A/B also increased 10- to 100-fold over time and was most abundant in the nasal cultures and SACs (Fig. 3A). Type I IFNs (IFN-α2 and IFN-β) were produced to a lesser extent than type III IFN. The concentration of IFN-α2 hardly increased after infection compared to uninfected controls, and IFN-β was 2- to 3-fold elevated in all cultures compared to uninfected controls (Fig. 3B). Overall, both rHRSVA11 and rHRSVB05 induced higher levels of IFNs at 2 DPI than rHRSVA2, which is in accordance with the percentages of EGFP+ surface area (Fig. 1). Notably, the interferon response clearly lagged behind the viral replication, and viral titers correlated positively with interferon production (Fig. S4). Early-stage inflammatory cytokine IP10 was increased in all the HRSV-infected airway cultures and also correlated positively with viral replication (Fig. 3C; Fig. S4). We also measured IL-6, IL-1β, tumor necrosis factor alpha (TNF-α), IFN-γ, IL-8, IL12p70, granulocyte-monocyte colony-stimulating factor

**FIG 1** Replication kinetics of rHRSVA2EGFP(5), rHRSVA11EGFP(5), and rHRSVB05EGFP(5) in nasal, bronchial, and small-airway cultures. Nasal cells (A), bronchial cells (B), and small-airway cells (C) were infected with rHRSVA2EGFP(5), rHRSVA11EGFP(5), or rHRSVB05EGFP(5) at a standardized low viral inoculum. The percentage of EGFP+ surface area was determined by confocal microscopy, and the viral titers were determined by endpoint titrations of apical washes (TCID₅₀/ml). One independent experiment is shown, and all experiments were performed in triplicate. Differences between the growth curves were statistically analyzed by two-way ANOVA (*, P = 0.05; **, P = 0.01; ***, P = 0.001; ****, P < 0.0001). Mean and individual replicates are shown.
HRSV replication kinetics in well-differentiated airway organoid cultures at ALI. In addition to studying HRSV replication kinetics and innate immune responses in commercially available primary cells, we also studied these in AOs cultured at ALI as described before (25). These AOs were obtained from adult human lung stem cells from the distal airways and cultured at ALI for 4 weeks to allow differentiation of the cells into pseudostratified epithelium, including ciliated epithelial cells. Cells were infected with a low standardized inoculum of rHRSV, and the replication kinetics, dissemination, cytopathology, and innate cytokine responses were assessed. In general, HRSV replication kinetics were comparable with the commercially available bronchial cultures: infection with the clinical isolate-based viruses resulted in a higher percentage virus-infected surface area (especially at 2 DPI), and infection with rHRSV-A strains resulted in higher viral titers over time (Fig. 4; Fig. S1). rHRSV A11 disseminated better than the other viruses, resulting in significantly more infected cells.

Cytopathology in well-differentiated airway organoid cultures at ALI. To assess the tropism of HRSV and the associated CPE, we used AOs cultured at ALI. First, we created organoids (spheroids in Matrigel) from human bronchial tissue obtained after lung resection surgery. We cultured these undifferentiated organoids in Matrigel for 10 to 14 days and then dissociated them into single cells. These cells were seeded on Transwell membranes and grown at ALI for 4 weeks, allowing differentiation. We characterized the cultures by hematoxylin and eosin (H&E) and IIF staining at 3 DPI. The uninfected cultures had multiple cell layers and an abundance of ciliated cells (Fig. 5A and C). HRSV infected mainly ciliated epithelial cells. Degenerated cilia, rounding of infected cells, and small syncytia were observed in infected cultures compared to uninfected controls, and the integrity of the tight junctions was affected by HRSV infection.
FIG 3  Type III IFN, type I IFN, and IP10 production in HRSV-infected nasal, bronchial, and small-airway cells. Nasal, bronchial, and small-airway cells were infected with either rHRSV\textsuperscript{A2EGFP}, rHRSV\textsuperscript{A11EGFP}, or rHRSV\textsuperscript{B05EGFP} at standardized low viral inoculum. Apical washes were taken at 0, 1, 2, and 3 days postinfection (DPI), and type III IFN (IL28A/B, IL-29) (A), type I IFN (IFN-\textalpha\textsuperscript{2} and IFN-\textbeta) (B), and IP10 (C) were quantified using the BD LEGENDplex human antivirus response panel. One independent experiment is shown, and all experiments were performed in triplicate. Mean and standard deviation are shown.
We observed an increase in mucus production and the formation of small channels (Fig. 5A and B), similar to the commercially available nasal and bronchial cultures (Fig. 2A and B; Fig. S1A and B). Differences in CPE between rHRSV-A and rHRSV-B strains were not observed.

**Cytokine production in well-differentiated airway organoid cultures at ALI.**

Next, we harvested culture supernatant from the apical side at 0, 1, 2, and 3 DPI and measured the same cytokines as measured in commercially obtained nasal, bronchial, and small-airway cells (Fig. 6; Fig. S5). We observed an increase in type III IFNs; IL-29 increased the most upon HRSV infection, but IL-28A/B was also elevated (Fig. 6A). ALI-differentiated AOs produced IFN-α, but IFN-β production was more pronounced (Fig. 6B). General inflammatory marker IP10 was increased after HRSV infection (Fig. 6C). Type III IFN, type I IFN, and IP10 were all induced by HRSV replication, indicated by a positive correlation

(Fig. 5B and D). We observed an increase in mucus production and the formation of small channels (Fig. 5A and B), similar to the commercially available nasal and bronchial cultures (Fig. 2A and B; Fig. S1A and B). Differences in CPE between rHRSV-A and rHRSV-B strains were not observed.

**FIG 4** Replication kinetics of rHRSV\(^{A11}\)EGFP(5), rHRSV\(^{A11}\)EGFP(5), and rHRSV\(^{B05}\)EGFP(5) in primary well-differentiated airway organoid cultures at ALI. Primary well-differentiated airway organoid cultures at ALI were infected with rHRSV\(^{A11}\)EGFP(5), rHRSV\(^{A11}\)EGFP(5), or rHRSV\(^{B05}\)EGFP(5) at a standardized low viral inoculum. The percentage EGFP\(^{+}\) surface area was determined by confocal laser scanning microscopy, and the viral titers were determined by endpoint titrations of the apical washes (TCID\(_{50}/\)ml). One representative experiment is shown that was performed in triplicate. Differences between the growth curves were statistically analyzed with a two-way ANOVA (*, \(P<0.05\)). Mean and individual replicates are shown.

**FIG 5** Immunohistochemistry and indirect immunofluorescence on primary well-differentiated airway organoid cultures at ALI infected with HRSV. Well-differentiated airway organoid cultures at ALI were infected with either rHRSV\(^{A11}\)EGFP(5), rHRSV\(^{A11}\)EGFP(5), or rHRSV\(^{B05}\)EGFP(5) at a standardized low viral inoculum. Samples were fixed in formalin at 3 days postinfection (DPI) and embedded in paraffin. (A and B) Paraffin-embedded slides were used for H&E staining and indirect immunofluorescence using antibodies against green fluorescent protein (HRSV, green), acetylated α-tubulin (cilia, red), and Hoechst (nuclei, blue). Arrows indicate putative mucus channels in the cultures. (C and D) Transwell filters were additionally stained with antibodies against zona-occludens 1 (tight junctions, magenta) and acetylated α-tubulin (cilia, orange). Representative images are shown of rHRSV\(^{A11}\).
between cytokine levels and viral loads (Fig. S6). IL-6, IL-1β, TNF-α, IFN-γ, IL-8, IL12p70, GM-CSF, and IL-10 were produced in small amounts (or not at all) in AOs after rHRSV infection (Fig. S7). Overall, cytokine profiles were similar to the cytokine profiles in the commercially purchased bronchial epithelial cells; only IL-28A/B was less produced in these cultures.

**HRSV-A and HRSV-B competition experiments in airway organoids cultures at ALL.** In infection experiments in nasal, bronchial, SACs, and AOs, rHRSVA11 has an infectivity advantage over rHRSVB05 when comparing both production of cell-free virus and percentage EGFP. To confirm this infectivity advantage of rHRSVA11 over rHRSVB05, we performed a direct competition experiment. We infected AOs cultured at ALL with rHRSVA11 expressing EGFP and rHRSVB05 expressing dTom. Both viruses were added simultaneously at the same low input, and infections were followed over time. Two different experimental setups were used, daily confocal microscopy accompanied by apical washes after infection (Fig. 7A) or daily confocal microscopy, but only performing an apical wash at 4 DPI (Fig. 7B). In both setups, we found that HRSVAA11 replicated to a significantly higher cell-free viral titer and disseminated to a larger virus-positive area than HRSVB05. We observed both single-infected (HRSVA11 positive or HRSVB05 positive) and double-infected cells (HRSVA11 and HRSVB05 positive). We quantified the percentage

---

**FIG 6** Type III IFN, type I IFN, and IP10 production in HRSV-infected primary well-differentiated airway organoid cultures at ALL. Well-differentiated airway organoid cultures at ALL were infected with either rHRSVA2EGFP(5), rHRSVA11EGFP(5), or rHRSVB05EGFP(5) at a standardized low viral inoculum. Apical washes were taken at 0, 1, 2, and 3 days postinfection (DPI), and type III IFN (IL28A/B, IL-29) (A), type I IFN (IFN-α2 and IFN-β) (B), and IP10 (C) were quantified using the BD LEGENDplex human antiviral response panel. One independent experiment is shown, and all experiments were performed in triplicate. Mean and standard deviation are shown.
of double-positive cells, which was about 5%. In conclusion, we observed that both viruses can spread well in the culture and were able to coinfect cells (Fig. 7A to D).

**DISCUSSION**

In this study, we aimed to compare the replicative fitness and HRSV-induced innate cytokine responses of rHRSV-A and rHRSV-B strains in disease-relevant cell culture models. We used two recombinant clinical isolate-based HRSV strains, rHRSVA11 and rHRSVB05, and one recombinant laboratory-adapted HRSV strain, rHRSVA2, to infect commercially available nasal, bronchial, and small-airway cultures. Epithelial cells from all anatomical locations were susceptible to HRSV infection despite the induction of a robust type III interferon response. Subgroup A viruses disseminated and replicated faster than the subgroup B virus. Additionally, we studied HRSV infection and innate responses in AO cultured at ALI. The results in this model were similar to the results in the commercially obtained bronchial cells. In summary, we show that HRSV replicates...
well in cells from both the upper and the lower airways, with a slight infectivity advantage for subgroup A viruses. That finding fits with clinical observations that HRSV-A causes more severe disease than HRSV-B. Lastly, we showed that AOs cultured at ALI are a valuable model for studying HRSV in vitro. This model can be used for future experiments studying intrinsic and extrinsic factors that influence HRSV infection.

HRSV susceptibility studies with cells from different anatomical sites of the respiratory tract have rarely been performed. We found that, with a relatively low standardized inoculum, nasal and bronchial cells seemed more susceptible than SACs. However, HRSV replicated and disseminated efficiently in all the cultures over time. HRSV replication kinetics in nasal and bronchial cultures have also been shown in a previous study in which they used well-differentiated nasal and bronchial epithelial cells (29). These results match with what is observed in HRSV-infected children, where viral loads in nasal aspirates and deep tracheal aspirates correlate (30). We show that HRSV replicates in SACs. Infection of smaller bronchioles in infants can lead to mechanical obstruction due to inflammatory response, one of the hallmarks of the pathogenesis of HRSV bronchiolitis (14). The combined results of our study and the previously mentioned studies highlight that HRSV efficiently replicates and disseminates in airway cells from different anatomical locations.

In human HRSV disease, ciliated epithelial cells are the main target cell, and the infection is mostly restricted to the luminal side of the airways (14). Several studies have shown this in vitro, and our results in primary cells and with clinical isolate-based viruses confirm these observations (12, 17, 31–33). Additionally, we observed clear CPE at 3 DPI, such as cilia degeneration and remodeling of the epithelium. Results in literature are conflicting: cilia degeneration, such as shorter and damaged cilia, was previously described in other studies using either (pediatric) well-differentiated primary bronchial or nasal epithelial cells in combination with both clinical isolates and laboratory-adapted viruses (17, 31, 34). However, in other studies with primary well-differentiated bronchial or nasal epithelial cells, syncytium formation or cell damage were not observed (12, 34). In the latter studies, the major difference was that another recombinant HRSV strain was used (rgRSV, an HRSV-A2-derived recombinant virus), a highly laboratory-adapted strain with green fluorescent protein in the first position of the genome.

Clinical manifestations in HRSV bronchiolitis patients include epithelial cell sloughing, cell death, increased mucus production leading to mucus plugs, and occasional syncytium formation (14). We did not measure cell death or epithelial cell sloughing in our model, but we observed an increase in mucus production upon HRSV infection. We also observed alterations of the epithelium, including loss of tight junction integrity, formation of small syncytia, and formation of channels through which mucus was transported (observational data). These observations have been described in other studies using (pediatric) well-differentiated primary epithelial cells (17, 31, 35, 36). There is one study that did not describe any cytopathology in well-differentiated primary nasal epithelial cells; in this study, laboratory-adapted strains (HRSV-A2 and HRSV-A long) were used at a low multiplicity of infection and measured up to 36 h postinfection (HPI) (37).

Although infection of well-differentiated primary airway cultures with HRSV has been described, studies directly comparing laboratory-adapted strains and clinical isolates or HRSV-A versus HRSV-B are rare. Since we used recombinant HRSV strains, we were able to show that clinical isolates disseminated faster at early time points (1 and 2 DPI) than the laboratory-adapted virus, measured by surface area of infected cells. We did not observe these differences in cell-free virus titers. A limitation when comparing different virus strains in different cell types is that the susceptibility, permissiveness, and cell receptor usage can be different for each cell type (38). However, we believe that dissemination (fluorescence surface area) in combination with CPE is a better proxy for human disease severity than cell-free virus titers. Other studies have
shown that HRSV-A2 replicates to higher or similar viral loads than clinical isolates, but this is based on TCID<sub>50</sub>/ml and not infected cells or infected surface area (17, 31, 32).

We also found that, in general, subgroup A viruses resulted in higher cell-free titers and percentage of virus-positive area than the subgroup B virus, which is in agreement with clinical observations that HRSV-A causes more severe disease (26). We also compared the infectivity of these viruses by both performing stand-alone infections and a direct competition experiment. rHRSVA11 always replicated and disseminated better than rHRSVB05, but both strains were able to disseminate and infect cells in the culture. We also found dual-infected cells in our cultures. In another study, rHRSVA11 expressing EGFP and rHRSVB05 expressing dTom were used in cotton rats and cotton rat cell lines. Occasional double-infected cells were observed, both in vitro and in vivo (27). Our data confirm these observations, with as added value that we use primary human epithelial cells. Future studies elucidating coinfections and the factors underlying the replicative advantage of HRSV-A subgroup viruses are required.

Early dissemination in the airways can be influenced by host innate immune responses. The postinfection cytokine response in our cultures was dominated by type III IFNs. Type I IFNs and IP10 were additionally produced as described previously (17, 31, 36, 37). We also measured background cytokine levels in our cultures, which is probably an inherent property of the cultures in combination with daily washing of the cells, which can cause immune activation. Nevertheless, infected cultures showed a clear increase in cytokine production. Surprisingly, the abundance of type III IFNs did not hinder HRSV replication; the innate immune response might either be too late or insufficient. Another option is that immune cells are required to clear the virus effectively. Experiments with IFNs and cocultures with innate immune cells would be better suited to study the interactions between innate cytokines and HRSV infections.

As experiments in commercial primary airway cultures are expensive and dependent on suppliers, we validated a robust model system to study HRSV infections. It has been reported that AOs are susceptible to HRSV infection and reproduce several characteristics of HRSV disease (epithelial cell shedding, mucus production) (22–24). However, these studies used AOs in a basement matrix. We decided to evaluate this model further by culturing in-house-developed AOs at ALI to create a well-differentiated stem cell-based epithelial cell model, reflecting the natural epithelial barrier in the human respiratory tract with a direct interface between air and submucosal fluids. We assessed replication kinetics of the three rHRSV strains and found that replication in AOs cultured at ALI was comparable to replication kinetics in bronchial cultures from Epithelix. Similar to observations in commercially available cells, we found that in AOs cultures at ALI, mainly ciliated cells were infected, with a loss of tight junction integrity and an increase in mucus production. Finally, we showed the cytokine response upon infection was dominated by type III IFNs. Also, IP10 was increased, which was shown previously in AO cultures in Matrigel (22). Taken together, we concluded that an AO-based well-differentiated model system accurately resembles commercially obtained bronchial cells.

In conclusion, we have shown that the combination of primary airway cultures with recombinant clinical isolate-based HRSV strains, expressing reporter proteins, is a powerful tool to study HRSV-host interactions in vitro. Additionally, we have refined stem cell-based cultures developed in-house for HRSV infection studies. Using these models, we demonstrated how HRSV rapidly disseminates throughout anatomically different airway cultures in the face of innate immune response. In follow-up experiments, we will use these models to investigate the influence of host factors, such as interactions with innate immune responses and bacterial and viral coinfections, on HRSV dissemination.

MATERIALS AND METHODS

Viruses. Virus stocks were grown on HEp-2 cells by inoculating cell pellets at a multiplicity of infection of 0.01 for 1 to 2 h at 37°C, followed by seeding into T175 cm<sup>2</sup> tissue culture flasks (for growth kinetics in HEp-2 cells, see Fig. S8 in the supplemental material). When 90 to 100% of CPE was observed, cells were
scraped from the flasks and sonicated three times for 30 s, and subsequently, cell debris was removed by centrifugation for 15 min at 600 × g. The supernatant was mixed with sucrose to a final concentration of 25% (vol/vol) for stability, snap-frozen, and stored at −80°C. rHRSVα (rHRSVαEGFP(5)) was commercially obtained from ViraTree (product no. R125), and previously rescued rHRSVα (rHRSVαEGFP(5), passage 5); rHRSVβ (rHRSVβEGFP(5), passage 6); and rHRSVαΔdTom(5), passage 7 have been described before (the 5 between brackets refers to the position of the additional transcriptional unit in the genome) (27, 28).

**Human primary airway culture and differentiation.** MucilAir (primary nasal or bronchial human airway epithelial cells) and SmallAir (primary small-airway human airway epithelial cells) were obtained from Epithelix (Epithelix Sàrl, Geneva, Switzerland) and cultured according to the manufacturer's instructions. The culturing of human airway organoids was developed in-house, and differentiation on ALI was performed as described before (22, 25). In short, nontumor lung tissue, obtained from patients undergoing lung resection surgery for lung cancer, was used to derive adult human lung stem cells from the distal airways (Medical Ethical Committee of the Erasmus MC Rotterdam, METC 2012-S12) (22). Undifferentiated AOs were cultured in Matrigel (Corning) droplets (with 250 μl) with 25% (vol/vol) CO2. To obtain differentiated organoid-derived cultures at ALI, organoids were made into single cells with TrypLE Express and subsequently seeded on Transwell membranes (Corning) coated with rat tail collagen type I (Fisher Scientific). The single AO cells were seeded in AO medium and complete base medium (CBM; Stemcell Technologies; PneumCult-ALI) at a 1:1 ratio. When a confluent monolayer was formed (2 to 4 days), the cultures were put on ALI in CBM. Cultures were differentiated for 4 weeks, and the medium was changed every 5 days.

**Virus quantification.** Growth kinetics in the primary airway cells cultured at ALI were assessed by washing the cultures twice with Dulbecco's phosphate-buffered saline (DPBS) with Ca and Mg (0.9 mM MgCl2 and 0.59 mM CaCl2), followed by HRSV inoculation from the apical side at a standardized low viral inoculum (multiplicity of infection, 0.5), based on titrations on HEP-2 cells, for 1 to 2 h at 37°C and 5% (vol/vol) CO2 (experiment performed once in triplicate). After inoculation, cultures were washed three times with DPBS plus Ca and Mg. At the indicated time points, supernatants from the apical side were collected by adding 200 μl Dulbecco's modified Eagle medium (DMEM) (catalog no. LO BE12-733F; Lonza), incubating for 10 min at 37°C and 5% (vol/vol) CO2, and harvesting for direct titration on HEP-2 cells (39). Leftover supernatant was kept for cytokine detection. Additionally, the percentage EGFP+ or dTom+ surface area was determined by imaging complete wells by performing tile scans on an LSM700 confocal microscope, analyzed with ZEN software (Zeiss) and Fiji (40). For the analysis of fluorescence-positive area, the tile scan was selected, and Fiji was used to automatically set the optimal brightness, contrast, and threshold. Then, the software measured the percentage fluorescence area, independent of particle size (pixels).

**Histology.** Primary airway cultures were fixed in 4% (wt/vol) paraformaldehyde (PFA) for at least 30 min, after which the filters from the Transwell were excised, stored in formalin, and subsequently embedded in paraffin. Thin sections (3 μm) were prepared from the formalin-fixed, paraffin-embedded tissues and stained using hematoxylin and eosin. For IIF staining, slides were incubated at 37°C overnight and then deparaffinized (twice for 4 min in xylene, twice for 2 min in 100% ethanol, once for 2 min in 96% ethanol, once for 2 min in 90% ethanol, once for 2 min in 70% ethanol, and, lastly, 5 min of PBS). Antigens were retrieved with citrate buffer (10 mM, pH 6.0 [Sigma]) (4.2 g C6H8O7·H2O in 2 liters Milli-Q, set pH, with 10N NaOH). Slides were blocked in 10% normal goat serum (NGS) in phosphate-buffered saline (PBS) for 30 min at room temperature (RT). Primary antibodies (acetylated α-tubulin [Santa Cruz Biotechnology, catalog no. sc-39350 AF488] and rabbit anti-GFP [Invitrogen, catalog no. A11122]) were added for 1 h of incubation at RT, and secondary antibodies (Alexa fluor 488 [Invitrogen, catalog no. A11012]) were added for 1 h of incubation at RT. After two washings, Hoechst (Thermo Scientific, catalog no. 62249) was added and incubated 15 min at RT. Samples were washed twice and mounted with Prolong Diamond antifade mounting medium and analyzed using an LSM700 confocal microscope, ZEN software (Zeiss), and Fiji (40).

**Immunofluorescence microscopy.** Transwell inserts were fixed in 4% (wt/vol) PFA for 30 min and then stored in PBS for further analysis. For indirect immunofluorescence staining, one-quarter of the filter was excised, washed twice, permeabilized in 0.2% Triton-X, and blocked in 10% NGS in staining buffer (DPBS with 150 mM MgCl2, 150 mM CaCl2, and 10 mM HEPES) for 30 min. The cells were incubated with conjugated mouse monoclonal antibodies for 60 min in staining buffer containing 10% NGS and 2% (wt/vol) bovine serum albumin (BSA). Tightly junctions were stained using anti-zona-occludens 1 (clone 1A12; Alexa Fluor 550; Santa Cruz Biotechnologies), and cilia were stained using anti-acetylated tubulin (Alexa Fluor 647; Santa Cruz Biotechnologies, clone 6-11B-1). In the last 10 min of the incubation with antibodies, Hoechst 33342 was added (Life Technologies/Invitrogen, catalog no. 10150888). After staining, the cells were washed three times with staining buffer and mounted in Prolong antifade mounting medium (Life Technologies/Invitrogen, catalog no. P36961). Samples were imaged on an LSM700 confocal microscope using ZEN software (Zeiss) and Fiji (40).

**Cytokine detection.** Cytokines were measured in apical and basolateral cell culture supernatant from the primary airway cells using a human antivirus response panel (13-plex) kit (LEGENDplex; BioLegend). In short, cell culture supernatant was mixed with beads coated with capture antibodies specific for IFN-α2, IFN-β, IL-2, IL-6, IL-8, IL-10, TNF-α, IL-12p70, GM-CSF, IP-10, and IL-1β, and incubated for 2 h. Beads were washed and incubated with biotin-labeled detection antibodies for 1 h, followed by a final incubation with streptavidin™. Beads were analyzed by flow cytometry, and final analysis was performed using the LEGENDplex analysis software v8.0. The quantity of each respective cytokine is calculated on basis of the intensity of the streptavidin™ signal and a freshly prepared standard curve (as described in Weiskopf et al.) (41).
**Supplemental Material**

Supplemental material is available online only.

**FIG S1**, TIF file, 0.4 MB.

**FIG S2**, TIF file, 2.6 MB.

**FIG S3**, TIF file, 2.6 MB.

**FIG S4**, TIF file, 1.3 MB.

**FIG S5**, TIF file, 1.2 MB.

**FIG S6**, TIF file, 0.7 MB.

**FIG S7**, TIF file, 0.7 MB.

**FIG S8**, TIF file, 2.4 MB.

**Acknowledgments**

We thank A. de Jong and L.J. Rennick for their contributions to this study.

**References**

1. Openshaw PJ, Chiu C, Culey FJ, Johansson C. 2017. Protective and harmful immunity to RSV infection. Annu Rev Immunol 35:501–532. https://doi.org/10.1146/annurev-immunol-051116-052206.

2. Nam HH, Ison MG. Respiratory syncytial virus infection in adults. 2019. BMJ 366:j5021. https://doi.org/10.1136/bmj.j5021.

3. Borchers AT, Chang C, Gershwin ME, Gershwin LJ. 2013. Respiratory syncytial virus - a comprehensive review. Clin Rev Allerg Immunol 45:331–379. https://doi.org/10.1007/s12016-013-8366-9.

4. Simoes EAF. 1999. Respiratory syncytial virus infection. Lancet 354:847–852. https://doi.org/10.1016/S0140-6736(99)00400-3.

5. Hall CB, Walsh EE, Long CE, Schnabel KC. 1991. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 163:693–698. https://doi.org/10.1093/infdis/163.4.693.

6. Lambert L, Sagfors AM, Openshaw PJM, Culey FJ. 2014. Immunity to RSV in early-life. Front Immunol 5:466. https://doi.org/10.3389/fimmu.2014.00466.

7. DeVincenzo JP, Atiken J, Harrison L. 2003. Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibody. J Pediatr 143:123–126. https://doi.org/10.1016/S0022-3476(03)00213-0.

8. Subramanian KNS, Weisman LE, Rhodes T, Ariagno R, Sánchez PJ, Steichen J, Givner LB, Jennings TL, Top FH, Carlin D, Connor E. 1998. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr Infect Dis J 17:110–115. https://doi.org/10.1097/00006454-199802000-00006.

9. Griffin MP, Yuen Y, Takas T, Domachowska JB, Madhi SA, Manzioni P, Simões EAF, Esser MT, Khan AA, Dubovsky F, Villafana T, DeVincenzo JP. 2020. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med 383:415–425. https://doi.org/10.1056/NEJMoa1913556.

10. Hall CB, Walsh EE, Hruska JF, Betts RF, Hall WJ. 1983. Ribavirin treatment of experimental respiratory syncytial viral infection. A controlled double-blind study in young adults. JAMA 249:2666–2670. https://doi.org/10.1001/jama.1983.0334030042027.

11. Simões EAF, Bont L, Manzioni P, Fauroux B, Paes E, Figueras-Aloy J, Checchia PA, Carbonell-Estrany X. 2018. Past, present and future approaches to the prevention and treatment of respiratory syncytial virus infection in children. Infect Dis Rev 8:7–120. https://doi.org/10.1007/s40121-018-0188-z.

12. Zhang L, Peeples ME, Boucher RC, Collins PL, Pickles RJ. 2002. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol 76:5654–5666. https://doi.org/10.1128/JVI.76.11.5654-5666.2002.

13. Piedimonte G, Perez MK. 2014. Respiratory syncytial virus infection and bronchiolitis. Pediatr Rev 35:519–530. https://doi.org/10.1542/pir.35-12-519.

14. Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS. 2007. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol 20:108–119. https://doi.org/10.1038/modpathol.3800725.

15. Smyth RL, Openshaw PJ. 2006. Bronchiolitis. Lancet 368:312–322. https://doi.org/10.1016/S0140-6736(06)66977-6.

16. Pandya MC, Callahan SM, Savchenko KG, Stobart CC. 2019. A contemporary review of respiratory syncytial virus (RSV) biology and strain-specific differences. Pathogens 8:67. https://doi.org/10.3390/pathogens8020067.

17. Villenave R, Thavagnanam S, Sarlang S, Parker J, Douglas I, Skibinski G, Heaney LG, McKaigue JP, Coyle PV, Shields MD, Power UF. 2012. In vitro modeling of respiratory syncytial virus infection of pediatric bronchial epithelium, the primary target of infection in vivo. Proc Natl Acad Sci U S A 109:5040–5045. https://doi.org/10.1073/pnas.1110203109.

18. Gray TE, Guzman K, Davis CW, Abdullah LH, Nettlesheim P. 1996. Murinecolary differentiation of serially passaged normal human tracheobronchial epithelial cells. Am J Respir Cell Mol Biol 14:104–112. https://doi.org/10.1165/ajrccmb.14.1.8534481.

19. Becker S, Soukup J, Yankaskas JR. 1992. Respiratory syncytial virus infection of human primary nasal and bronchial epithelial cell cultures and bronchoalveolar macrophages. Am J Respir Cell Mol Biol 6:369–374. https://doi.org/10.1165/ajrccmb/6.4.369.

20. Groves HE, Guo-Parke H, Broadbent L, Shields MD, Power UF. 2018. Characterisation of morphological differences in well-differentiated nasal epithelial cell cultures from preterm and term infants at birth and one-year. PLoS One 13:e0201328. https://doi.org/10.1371/journal.pone.0201328.

21. Ramani S, Crawford SE, Blutt SE, Estes MK. 2018. Human organoid cultures: transformative new tools for human virus studies. Curr Opin Virol 29:79–86. https://doi.org/10.1016/j.coviro.2018.04.001.

22. Sachs N, Papaspyropoulos A, Zomer-van Ommen DD, Heo I, Böttiger L, Klay D, Weeber F, Huelsez-Prince G, Iakobachvili N, Amatgadlin GM, Ligt J, Hoeck A, Proost N, Viveen MC, Lyubimova A, Teeven L, Derakhshan S, Korting J, Begthel H, Dekkers JF, Kumawat K, Ramos E, Oosterhout MF, Offerhaus GJ, Wiener DJ, Olimpio EP, Dijkstra KK, Smit EF, Linden M, Jaksani S, Ven M, Jonkers J, Rios AC, Voest EE, Mooreel CH, Ent CK, Cuppen E, Oudenaarden A, Coenjaerts FE, Meysaard L, Bont LJ, Peters PJ, Tans SJ, Zon JS, Boj SF, Vries RG, Beekman JM, Cvekl. 2019. Long-term expanding human airway organoids for disease modeling. EMBO J 38:e100300. https://doi.org/10.15252/embj.2018100300.

23. Porotto M, Ferren M, Chen YW, Siu Y, Makhous N, Rima B, Briese T, Grefenstette A, Sneoeck HW, Moscona A. 2019. Authentic modeling of human respiratory virus infection in human pluripotent stem cell-derived lung organoids. mBio 10:e00723-19. https://doi.org/10.1128/mBio.00723-19.

24. Chen YW, Huang SX, De Carvalho ALRT, Ho SH, Islam MN, Volpi S, Notarangelo LD, Ciancanelli M, Casanova JL, Bhattacharya J, Liang AF, Zon JS, Klay D, Weeber F, Huelsez-Prince G, Iakobachvili N, Tafreshi H. 2020. Organoid modeling of respiratory virus infection in human pluripotent stem cell-derived lung organoids. mBio 11:e0201328. https://doi.org/10.1128/mBio.0201328.
dimensional model of human lung development and disease from pluripotent stem cells. Nat Cell Biol 19:542–549. https://doi.org/10.1038/ncb3510.

25. Lamers MM, Beumer J, van der Vaart J, Knoops K, Puschhof J, Breugem Tl, Ravelli RBG, Paul van Schayck J, Mykytyn AZ, Duimel HQ, van Donselaar E, Riesebosch S, Kuipers HJH, Schipper D, van de Wetering WJ, de Graaf M, Koopmans M, Cuppen E, Peters PJ, Haagmans BL, Clevers H. 2020. SARS-CoV-2 productively infects human gut enterocytes. Science 369:50–54. https://doi.org/10.1126/science.abc1669.

26. Vandini S, Biagi C, Lanari M. 2017. Respiratory syncytial virus: the influence of serotype and genotype variability on clinical course of infection. Int J Mol Sci 18:1717. https://doi.org/10.3390/ijms18081717.

27. Rennick LJ, Nambulli S, Lemon K, Olinger GY, Crossland NA, Millar EL, Duprex WP. 2020. Recombinant subtype A and B human respiratory syncytial virus clinical isolates co-infect the respiratory tract of cotton rats. J Gen Virol 101:1056–1068. https://doi.org/10.1099/jgv.0.001471.

28. Lemon K, Nguyen DT, Ludlow M, Rennick LJ, Yüksel S, van Amerongen G, McQuaid S, Rima BK, de Swart RL, Duprex WP. 2015. Recombinant subgroup B human respiratory syncytial virus expressing enhanced green fluorescent protein efficiently replicates in primary human cells and is virulent in cotton rats. J Virol 89:2849–2856. https://doi.org/10.1128/JVI.03587-14.

29. Hong GP, Canning P, Douglas J, Villenave R, Heaney LG, Lyons JD, Shields MD, Power UF. 2013. Relative respiratory syncytial virus cytopathogenesis in upper and lower respiratory tract epithelium. Am J Respir Crit Care Med 188:842–851. https://doi.org/10.1164/rcrm.201304-0750OC.

30. Tristram DA, Hicks W, Hard R. 1998. Respiratory syncytial virus and human bronchial epithelium. Arch Otolaryngol Head Neck Surg 124:777–783. https://doi.org/10.1001/archotol.124.7.777.

31. Persson BD, Jaffe AB, Fearns R, Danahay H. 2014. Respiratory syncytial virus can infect basal cells and alter human airway epithelial differentiation. PLoS One 9:e102368. https://doi.org/10.1371/journal.pone.0102368.

32. Wright PF, Ikizler MR, Gonzales RA, Carroll KN, Johnson JE, Werkhaven JA. 2005. Growth of respiratory syncytial virus in primary epithelial cells from the human respiratory tract. J Virol 79:8651–8654. https://doi.org/10.1128/JVI.79.13.8651-8654.2005.

33. Il Jeong K, Piepenhagen PA, Kishko M, DiNapoli JM, Groppo RP, Zhang L, Elmonosy J, Kleanthous H, Delarueque S, Parras M. 2015. CX3CR1 is expressed in differentiated human ciliated airway cells and co-localizes with respiratory syncytial virus on cilia in a G protein-dependent manner. PLoS One 10:e0130517. https://doi.org/10.1371/journal.pone.0130517.

34. Das S, Palmer OP, Leight WD, Surowitz JB, Pickles RJ, Randell SH, Buchman CA. 2005. Cytokine amplification by respiratory syncytial virus infection in human nasal epithelial cells. Laryngoscope 115:764–768. https://doi.org/10.1001/01.MLG.0000159527.76949.93.

35. Reed LJ, Muench H. 1938. A simple method of estimating fifty per cent endpoints. American J Hygiene 27:493–497. https://doi.org/10.1093/oxfordjournals.aje.a118408.

36. Persson BD, Jaffe AB, Fearns R, Danahay H. 2014. Respiratory syncytial virus can infect basal cells and alter human airway epithelial differentiation. PLoS One 9:e102368. https://doi.org/10.1371/journal.pone.0102368.

37. Okabayashi T, Kojima T, Masaki T, Yokota S, Imaiizumi T, Tsutsumi H, Himi T, Fuji J, Savada N. 2011. Type-III interferon, not type-I, is the predominant interferon induced by respiratory viruses in nasal epithelial cells. Virus Res 160:360–366. https://doi.org/10.1016/j.virusres.2011.07.011.

38. Johnson SM, McNally BA, Ioanidis I, Flano E, Teng MN, Oomens AG, Walsh EE, Peeples ME. 2015. Respiratory syncytial virus uses CX3CR1 as a receptor on primary human airway epithelial cultures. PLoS Pathog 11: e1005318. https://doi.org/10.1371/journal.ppat.1005318.

39. Weiskopf D, Schmitz KS, Raadsen MP, Krysiak A, Okba NMA, Endeman H, Walsh EE, Peeples ME, Powis J, N simulator. 2020. Recombinant subtype A and B human respiratory syncytial virus efficiently replicates in primary human cells and is virulent in cotton rats. J Virol 89:2849–2856. https://doi.org/10.1128/JVI.03587-14.

40. Il Jeong K, Piepenhagen PA, Kishko M, DiNapoli JM, Groppo RP, Zhang L, Elmonosy J, Kleanthous H, Delarueque S, Parras M. 2015. CX3CR1 is expressed in differentiated human ciliated airway cells and co-localizes with respiratory syncytial virus on cilia in a G protein-dependent manner. PLoS One 10:e0130517. https://doi.org/10.1371/journal.pone.0130517.

41. Reed LJ, Muench H. 1938. A simple method of estimating fifty per cent endpoints. American J Hygiene 27:493–497. https://doi.org/10.1093/oxfordjournals.aje.a118408.

42. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A. 2012. Fiji: an open-source platform for biological-image analysis. Nat Methods 9:676–682. https://doi.org/10.1038/nmeth.2019.

43. Buchman CA. 2005. Cytokine amplification by respiratory syncytial virus infection in human nasal epithelial cells. Laryngoscope 115:764–768. https://doi.org/10.1001/01.MLG.0000159527.76949.93.